Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN UFH versus MIRADON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN UFH versus MIRADON.
Heparin (UFH) vs MIRADON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, inducing a conformational change that accelerates the inactivation of thrombin (factor IIa) and factor Xa, thereby inhibiting coagulation.
MIRADON (anagrelide) inhibits cyclic nucleotide phosphodiesterase and the release of arachidonic acid from phospholipids, possibly by inhibiting phospholipase A2. It also suppresses megakaryocyte maturation and platelet production.
Intravenous: Initial bolus of 80 units/kg (or 5000 units) followed by continuous infusion of 18 units/kg/h (or 1300 units/h), adjusted to maintain aPTT 1.5-2.5 times control. Subcutaneous: 5000 units every 8-12 hours for prophylaxis.
2.5 mg orally twice daily (total daily dose 5 mg)
None Documented
None Documented
0.5–2 hours (dose-dependent; at therapeutic doses, ~1–2 h; with higher doses, up to 2.5 h). Clinical context: shorter half-life in pulmonary embolism; prolonged in hepatic or renal impairment.
Terminal elimination half-life is 8-12 hours in adults with normal renal function. In patients with creatinine clearance <30 mL/min, half-life may extend to 20-30 hours. The half-life supports twice-daily dosing in most patients.
Primarily cleared via reticuloendothelial system and metabolism; renal excretion of unchanged drug is minimal (<5%).
Renal excretion of unchanged drug accounts for 60-70% of the administered dose. Fecal/biliary excretion accounts for 20-25%, with the remainder as oxidative metabolites. Up to 10% is eliminated as glucuronide conjugates.
Category A/B
Category C
Anticoagulant
Anticoagulant